Stock Report

All about this stock under one free report Last Updated: 25-Sep-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Sudeep Pharma Peer Comparison

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: SUDEEPPHRM | BSE: 544619

₹1,164.90

up-down-arrow ₹21.50 (1.88%)

As on 25-Sep-2026IST

Market cap

info icon

₹13,092 Cr

Revenue (TTM)

info icon

₹676 Cr

P/E Ratio

info icon

71.7

P/B Ratio

info icon

14.2

Div. Yield

info icon

0.1 %

Edit peer-selector-edit
Sudeep Pharma Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Market cap (₹ Cr)
 13,092 37,220 27,969 16,771 15,201
Revenue (₹ Cr)
 676 9,683 2,372 2,590 1,108
Net Profit (₹ Cr)
 183.60 1,018.97 497.77 603.02 270.18
Net Margin (%)
 26.06 10.47 20.72 22.63 23.29
RoE (%)
 22.72 21.30 28.49 19.61 14.45
Price to Earnings
 71.68 36.80 56.19 27.81 55.20
Price-To-Book
 14.17 7.12 13.84 4.81 7.33

Income Statement (₹ Cr)

Sudeep Pharma Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Operating Revenue arrow
675.61 9,683.45 2,371.81 2,590.40 1,108.39
Total Income arrow
704.48 9,730.84 2,402.61 2,664.23 1,159.90
Total Expenditure arrow
442.67 7,739.53 1,608.91 1,753.71 720.01
EBITDA arrow
232.94 1,943.92 762.90 836.69 388.38
Depreciation arrow
15.56 425.10 98.11 78.88 74.78
EBIT arrow
217.38 1,518.82 664.79 757.81 313.60
Interest arrow
7.96 148.45 26.33 5.43 0.26
Other Income arrow
28.87 47.39 30.80 73.83 51.50
Exceptional Items arrow
0.00 -27.85 0.00 -25.66 -3.28
Profit before Tax arrow
238.30 1,389.91 669.26 800.55 361.56
Provision for Tax arrow
54.69 370.94 171.48 197.53 91.39
Profit after Tax arrow
183.60 1,018.97 497.77 603.02 270.18

Liabilities (₹ Cr)

Sudeep Pharma Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Shareholder's Funds arrow
883.34 4,950.03 1,874.47 3,332.13 2,017.06
Minority Interest arrow
-0.97 -7.58 0.00 0.00 2.51
Non-Current Liabilities arrow
74.82 723.57 345.47 142.73 50.51
Current Liabilities arrow
201.96 3,912.24 710.20 508.04 169.08
Total Liabilities arrow
1,174.38 9,514.48 2,930.14 4,157.10 2,231.79

Assets (₹ Cr)

Sudeep Pharma Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Non-Current Assets arrow
477.92 3,392.16 1,290.62 1,321.38 957.22
Current Assets arrow
623.97 5,612.10 1,483.13 2,649.36 1,250.11
Total Assets arrow
1,174.38 9,514.48 2,930.14 4,157.10 2,231.79
Total Debt* arrow
148.29 1,204.08 196.61 0.00 0.00
Net Current Assets arrow
422.01 1,699.86 772.93 2,141.33 1,081.04
Contingent Liabilities arrow
-- 258.92 13.18 4.82 3.76

Cashflow (₹ Cr)

Sudeep Pharma Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Cash From Operating Activities arrow
69.55 943.55 346.68 565.41 266.88
Cash Flow from Investing Activities arrow
-330.93 -1,193.06 -423.73 -570.15 -142.72
Cash from Financing Activities arrow
247.29 343.43 20.98 -64.34 -112.88
Net Cash Inflow / Outflow arrow
-14.09 93.92 -56.08 -69.08 11.28

Ratios

Profitability Ratios

 Sudeep Pharma Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
ROCE (%) arrow
28.50 25.25 27.50 24.61 18.04
ROE (%) arrow
22.72 21.30 28.49 19.61 14.45
ROA (%) arrow
31.25 11.42 19.48 16.31 12.66
EBIT Margin (%) arrow
32.18 15.68 28.03 29.25 28.29
Net Margin (%) arrow
26.06 10.47 20.72 22.63 23.29
Cash Profit Margin (%) arrow
0.00 0.00 0.00 0.00 0.00

Growth Ratios

 Sudeep Pharma Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Revenue Growth (%) arrow
23.56 18.36 78.33 7.93 -6.72
EBIT Growth (%) arrow
12.00 30.43 303.07 19.88 -26.64
Net Profit Growth (%) arrow
20.07 32.39 182.61 21.66 -24.38
EPS Growth (%) arrow
50.65 36.68 277.72 25.42 -21.99
Book Value Growth (%) arrow
79.97 11.36 22.95 18.43 11.27

Valuation Ratios

 Sudeep Pharma Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Price / Earnings arrow
69.66 35.79 56.65 26.87 54.90
Price / Book Value arrow
14.33 7.07 13.95 4.80 7.36
Dividend Yield (%) arrow
0.13 0.19 0.15 0.37 0.52
EV/EBITDA arrow
56.97 19.56 36.75 19.06 38.20
Market Cap (₹ Cr) arrow
6,690.53 30,257.56 15,412.11 11,956.86 10,627.92

Solvency Ratios

 Sudeep Pharma Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Debt to Equity arrow
0.04 0.05 0.09 0.00 0.00
Short term debt to equity ratio arrow
0.12 0.16 -- -- --
Current Ratio arrow
3.09 1.43 2.09 5.21 7.39
Quick Ratio arrow
2.02 0.82 1.37 3.85 5.46
Interest Coverage arrow
30.94 10.36 26.41 148.49 1,386.30

Operating Efficiency Ratios

 Sudeep Pharma Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Debtors to sales (%) arrow
33.68 26.46 22.82 41.42 41.52
Asset Turnover arrow
1.15 1.09 0.93 0.70 0.52
Receivable days arrow
115.16 88.68 77.32 144.58 169.86
Inventory Days arrow
96.15 84.11 80.83 96.67 97.92
Payable days arrow
106.08 176.65 125.94 135.45 159.68
Cash Conversion Cycle arrow
105.23 -3.86 32.22 105.80 108.11
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...